ABVC BioPharma, Inc. announced that Dr. Richard King, the Company's Chief Scientific Officer of the company, notified the Company of his resignation, effective June 13, 2023. The Company's board of directors appointed Dr. Tsung-Shann (T.S.) Jiang to replace Dr. King as the Company's CSO. Dr. Jiang currently serves as the Company's Chief Strategy Officer and is one of the Company's directors.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8577 USD | +0.91% | +10.50% | -26.06% |
17/05 | ABVC BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
09/05 | Abvc Biopharma, Inc. Enters into A Definitive Agreement with Oncox Biopharma, Inc | CI |
1st Jan change | Capi. | |
---|---|---|
-26.06% | 92.85L | |
+16.93% | 12TCr | |
+17.01% | 11TCr | |
-7.23% | 2.36TCr | |
+1.98% | 2.26TCr | |
-14.29% | 1.73TCr | |
-6.79% | 1.76TCr | |
-37.63% | 1.76TCr | |
+2.17% | 1.35TCr | |
+24.42% | 1.13TCr |
- Stock Market
- Equities
- ABVC Stock
- News ABVC BioPharma, Inc.
- ABVC BioPharma, Inc. Announces Executive Changes